Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva Acquires Generics Maker Taiyo

by Michael McCoy
May 23, 2011 | A version of this story appeared in Volume 89, Issue 21

Israel’s Teva Pharmaceutical Industries has agreed to acquire 57% of Taiyo Pharmaceutical Industry for $460 million in cash. Teva is also extending an offer to buy the rest of Taiyo; the overall transaction values the Japanese firm at $1.3 billion. According to Teva, Taiyo is Japan’s third-largest generic drug company, with 2010 sales of $530 million. The additional sales will help Teva beat its goal of having $1 billion in annual Japanese sales by 2015. Japan, the world’s second-largest drug market, has a relatively low generics penetration of 23%, Teva notes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.